Quinolinyl Nitrone RP19 Induces Neuroprotection after Transient Brain Ischemia

ACS Chemical Neuroscience

Volumn 8, Issue 10, 2017, Pages 2202-2213

  Ayuso, Maria I ^a,c,d   Martínez Alonso, Emma ^a   Chioua, Mourad ^b   Escobar Peso, Alejandro ^a,b   Gonzalo Gobernado, Rafael ^d   Montaner, Joan ^c,d   Marco Contelles, José ^b   Alcázar, Alberto ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

animal ischemia models; ischemic stroke; Neuronal cultures; neuroprotection; oxidative stress; quinolyl nitrone

Indexed keywords

CITICOLINE; DISUFENTON SODIUM; NEUROPROTECTIVE AGENT; NITRONE DERIVATIVE; QUINOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RP 19; UNCLASSIFIED DRUG; NITROGEN OXIDE; NITRONES;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; CELL VIABILITY ASSAY; CLINICAL EVALUATION; CLINICAL OUTCOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVALESCENCE; DRUG DOSE COMPARISON; EMBRYO; EXPERIMENTAL BRAIN INJURY; FOUR VESSEL OCCLUSION-INDUCED STROKE; FUNCTIONAL STATUS; GRIP STRENGTH; GRIP STRENGTH TEST; HIPPOCAMPAL CA1 REGION; LIPID PEROXIDATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIMARY CELL CULTURE; PRIORITY JOURNAL; RAT; REOXYGENATION; REPERFUSION INJURY; TRANSIENT ISCHEMIC ATTACK; ANIMAL; BRAIN; BRAIN ISCHEMIA; CELL DEATH; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; DRUG EFFECT; METABOLISM; NERVE CELL; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL DEATH; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; NEURONS; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES; QUINOLINES; RATS, SPRAGUE-DAWLEY; STROKE;

EID: 85030099547     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.7b00126     Document Type: Article

References (37)

1. Becker, K. J. and Brott, T. G. (2005) Approval of the MERCI clot retriever: a critical view Stroke 36, 400-403 10.1161/01.STR.0000153056.25397.ff
2. The Penumbra Pivotal Stroke Trial Investigators (2009) The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease Stroke 40, 2761-2768 10.1161/STROKEAHA.108.544957
3. Koh, J. S., Lee, S. J., Ryu, C. W., and Kim, H. S. (2012) Safety and efficacy of mechanical thrombectomy with solitaire stent retrieval for acute ischemic stroke: a systematic review Neurointervention. 7, 1-9 10.5469/neuroint.2012.7.1.1
4. Lees, K. R., Bluhmki, E., von Kummer, R., Brott, T. G., Toni, D., Grotta, J. C., Albers, G. W., Kaste, M., Marler, J. R., Hamilton, S. A., Tilley, B. C., Davis, S. M., Donnan, G. A., and Hacke, W. (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375, 1695-1703 10.1016/S0140-6736(10)60491-6
5. Balami, J. S., Sutherland, B. A., and Buchan, A. M. (2013) Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke CNS Neurol. Disord.: Drug Targets 12, 155-169 10.2174/18715273112119990050
6. Nicole, O., Docagne, F., Ali, C., Margaill, I., Carmeliet, P., MacKenzie, E. T., Vivien, D., and Buisson, A. (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling Nat. Med. 7, 59-64 10.1038/83358
7. Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., Schneider, D., von Kummer, R., Wahlgren, N., and Toni, D. (2008) Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke N. Engl. J. Med. 359, 1317-1329 10.1056/NEJMoa0804656
8. Hussein, H. M., Georgiadis, A. L., Vázquez, G., Miley, J. T., Memon, M. Z., Mohammad, Y. M., Christoforidis, G. A., Tariq, N., and Qureshi, A. I. (2010) Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study AJNR Am. J. Neuroradiol. 31, 454-458 10.3174/ajnr.A2006
9. Green, A. R. and Shuaib, A. (2006) Therapeutic strategies for the treatment of stroke Drug Discovery Today 11, 681-693 10.1016/j.drudis.2006.06.001
10. Floyd, R. A., Kopke, R. D., Choi, C. H., Foster, S. B., Doblas, S., and Towner, R. A. (2008) Nitrones as therapeutics Free Radical Biol. Med. 45, 1361-1374 10.1016/j.freeradbiomed.2008.08.017
11. Doggrell, S. A. (2006) Nitrone spin on cerebral ischemia Curr. Opin. Invest. Drugs. 7, 20-24
12. Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hardemark, H. G., and Wasiewski, W. W. (2006) NXY-059 for acute ischemic stroke N. Engl. J. Med. 354, 588-600 10.1056/NEJMoa052980
13. Green, A. R., Ashwood, T., Odergren, T., and Jackson, D. M. (2003) Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059 Pharmacol. Ther. 100, 195-214 10.1016/j.pharmthera.2003.07.003
14. Savitz, S. I. (2007) A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal models of stroke Exp. Neurol. 205, 20-25 10.1016/j.expneurol.2007.03.003
15. Bath, P. M., Gray, L. J., Bath, A. J., Buchan, A., Miyata, T., and Green, A. R. (2009) Effects of NXY-059 in experimental stroke: An individual animal meta-analysis Br. J. Pharmacol. 157, 1157-1171 10.1111/j.1476-5381.2009.00196.x
16. Diener, H. C., Lees, K. R., Lyden, P., Grotta, J., Dávalos, A., Davis, S. M., Shuaib, A., Ashwood, T., Wasiewski, W., Alderfer, V., Hardemark, H. G., and Rodichok, L. (2008) NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials Stroke 39, 1751-1758 10.1161/STROKEAHA.107.503334
17. Green, A. R., Lanbeck-Vallén, K., Ashwood, T., Lundquist, S., Lindstrom Böö, E., Jonasson, H., and Campbell, M. (2006) Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia Brain Res. 1072, 224-226 10.1016/j.brainres.2005.12.035
18. Weber, J., Slemmer, J., Shacka, J., and Sweeney, M. (2008) Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging Curr. Med. Chem. 15, 404-414 10.2174/092986708783497337
19. Lapchak, P. A., Schubert, D. R., and Maher, P. A. (2011) De-risking of stilbazulenyl nitrone (STAZN), a lipophilic nitrone to treat stroke using an unique panel of in vitro assays Transl. Stroke Res. 2, 209-217 10.1007/s12975-011-0071-7
20. Sun, Y., Yu, P., Zhang, G., Wang, L., Zhong, H., Zhai, Z., Wang, L., and Wang, Y. (2012) Therapeutic effects of tetramethylpyrazine nitrone in rat ischemic stroke models J. Neurosci. Res. 90, 1662-1669 10.1002/jnr.23034
21. Villamena, F. A., Das, A., and Nash, K. M. (2012) Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics Future Med. Chem. 4, 1171-1207 10.4155/fmc.12.74
22. Samadi, A., Soriano, E., Revuelta, J., Valderas, C., Chioua, M., Garrido, I., Bartolomé, B., Tomassolli, I., Ismaili, L., González-Lafuente, L., Villarroya, M., García, A. G., Oset-Gasque, M. J., and Marco-Contelles, J. (2011) Synthesis, structure, theoretical and experimental in vitro antioxidant/pharmacological properties of α-aryl, N-alkyl nitrones, as potential agents for the treatment of cerebral ischemia Bioorg. Med. Chem. 19, 951-960 10.1016/j.bmc.2010.11.053
23. Chioua, M., Sucunza, D., Soriano, E., Hadjipavlou-Litina, D. J., Alcázar, A., Ayuso, I., Oset-Gasque, M. J., González, M. P., Monjas, L., Rodríguez-Franco, M. I., Marco-Contelles, J., and Samadi, A. (2012) α-Aryl-N-alkyl nitrones, as potential agents for stroke treatment: Synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties J. Med. Chem. 55, 153-168 10.1021/jm201105a
24. Ayuso, M. I., Chioua, M., Martínez-Alonso, E., Soriano, E., Montaner, J., Masjuán, J., Hadjipavlou-Litina, D. J., Marco-Contelles, J., and Alcázar, A. (2015) CholesteroNitrones for stroke J. Med. Chem. 58, 6704-6709 10.1021/acs.jmedchem.5b00755
25. Love, S. (1999) Oxidative stress in brain ischemia Brain Pathol. 9, 119-131 10.1111/j.1750-3639.1999.tb00214.x
26. Hurtado, O., Moro, M. A., Cárdenas, A., Sánchez, V., Fernández-Tomé, P., Leza, J. C., Lorenzo, P., Secades, J. J., Lozano, R., Dávalos, A., Castillo, J., and Lizasoain, I. (2005) Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport Neurobiol. Dis. 18, 336-345 10.1016/j.nbd.2004.10.006
27. Warner, D. S., Sheng, H., and Batinic-Haberle, I. (2004) Oxidants, antioxidants and the ischemic brain J. Exp. Biol. 207, 3221-3231 10.1242/jeb.01022
28. Ayuso, M. I., Martínez-Alonso, E., Cid, C., de Lecinana, M. A., and Alcázar, A. (2013) The translational repressor eIF4E-binding protein 2 (4E-BP2) correlates with selective delayed neuronal death after ischemia J. Cereb. Blood Flow Metab. 33, 1173-1181 10.1038/jcbfm.2013.60
29. Rami, A., Bechmann, I., and Stehle, J. H. (2008) Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia Prog. Neurobiol. 85, 273-296 10.1016/j.pneurobio.2008.04.003
30. Bederson, J. B., Pitts, L. H., Germano, S. M., Nishimura, M. C., Davis, R. L., and Bartkowski, H. M. (1986) Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats Stroke 17, 1304-1308 10.1161/01.STR.17.6.1304
31. Escobar-Peso, A., Chioua, M., Frezza, V., Martínez-Alonso, E., Marco-Contelles, J., and Alcázar, A. (2017) Nitrones, old fellows for new therapies in ischemic stroke. In Neuroprotective Therapy for Stroke and Ischemic Disease (Lapchak, P. A. and Zhang, J., Eds.), pp 251-283, Springer, New York 10.1007/978-3-319-45345-3-9.
32. Arundine, M. and Tymianski, M. (2004) Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury Cell. Mol. Life Sci. 61, 657-668 10.1007/s00018-003-3319-x
33. Barone, F. C. (2010) Post-stroke pharmacological intervention: promoting brain recovery from injury in the future Neuropharmacology 59, 650-653 10.1016/j.neuropharm.2010.08.016
34. Quevedo, C., Salinas, M., and Alcázar, A. (2003) Initiation factor 2B activity is regulatad by protein phosphatase 1, which is activated by the mitogen-activated protein kinase-dependent pathway in insulin-like growth factor 1-stimulated neuronal cells J. Biol. Chem. 278, 16579-16586 10.1074/jbc.M212936200
35. Alcázar, A., Regidor, I., Masjuán, J., Salinas, M., and álvarez-Cermeno, J. C. (2000) Axonal damage induced by cerebrospinal fluid from patients with relapsing-remitting multiple sclerosis J. Neuroimmunol. 104, 58-67 10.1016/S0165-5728(99)00225-8
36. García-Bonilla, L., Cid, C., Alcázar, A., Burda, J., Ayuso, I., and Salinas, M. (2007) Regulation proteins of eukaryotic initiation factor 2-alpha subunit (eIF2α) phosphatase, under ischemic reperfusion and tolerance J. Neurochem. 103, 1368-1380 10.1111/j.1471-4159.2007.04844.x
37. Morancho, A., García-Bonilla, L., Barceló, V., Giralt, D., Campos-Martorell, M., García, S., Montaner, J., and Rosell, A. (2012) A new method for focal transient cerebral ischaemia by distal compression of the middle cerebral artery Neuropathol. Appl. Neurobiol. 38, 617-627 10.1111/j.1365-2990.2012.01252.x